Latest Breaking News On - யாடின் சுனேஜா - Page 1 : vimarsana.com
Regeneron Pharmaceuticals : sees uptick in COVID-19 therapy use as cases rise
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Arena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Regeneron Pharmaceuticals Inc (REGN) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
5 Min Read
(Reuters) -Biogen Inc’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare.
FILE PHOTO: Aduhelm, Biogen s controversial recently approved drug for early Alzheimer s disease, is seen at Butler Hospital, one of the clinical research sites in Providence, Rhode Island, U.S. June 16, 2021. Jessica Rinaldi/Pool via REUTERS
An influential panel of medical experts also voted unanimously that there is no evidence that the drug, Aduhelm, provides a net health benefit to patients.
© Reuters. FILE PHOTO: Aduhelm, Biogen’s recently approved controversial drug for early Alzheimer’s disease, is seen at Butler Hospital in one of the clinical research sites conducted on June 16, 2021 in Providence, Rhode Island, USA. Via Jessica Rinaldi / Pool REUTERS
Deena by Beasley
(Reuters) – Biogen Inc.’s Alzheimer’s drug, the first new treatment for the disease to steal memory for nearly 20 years, hit new hurdles on Thursday as some hospitals refused to use it and health insurance delayed decision while awaiting Medicare coverage conditions .
A working group of medical experts has also unanimously voted that there is no Aduhelm drug that offers a net health benefit.